Quote:

---

CDTX - a competitor to CYDY's CCR5 MOA?

---

Not a CCR5 blocker it downregulates CCL5 via downregulation of CD73.The second part of the drug downregulates PD-1.

Leronlimab blocks CCL5 for the CCR5 receptor only but allows it's binding by other receptors. Leronlimab would also cause moderate downregulation through the feedback mechanism between CCR5 and CCL5. Leronlimab also significantly reduces PD-L1 the ligand for PD-1.

Their drug CBO421 would not have the other effects that leronlimab has on tumors and if CCL5 was downregulated to much it would act as an immune suppressor limiting the ability of the immune system to fight the tumor. Which can be a problem when you target one part of the system that affects all receptors.